Hi all
Not sure if anybody has put this up yet, but thought I'd share my high level notes on MSB's cash forecast without taking into account any revenue from Temcell:
Opening Balance December 2016 = US$33.9m
MNK January 2017 = +US$21.7m
Placement March 2017 = +US$40.0m
Q3 cash outflow = -US$27.0m
Forecast March17 = US$68.6m
Aust Gov rebate = +US$5.0m
Q4 cash outflow = -US$27.0m
Forecast June17 = US$46.6m
FY18 Q1 outflow = -US$27.0m
**MNK deal = +US$XXXm?
Forecast Sep17=US$19.6m +US$XXXm?
Other than the MNK deal, here are the potential sources of material cash injections throughout 2017/early 2018:
- Temcell sales ramping up
- Japan/China deal on RA/CLBP/CHF (can be approved on P2 data)
- RA partner (US)
- CHF partner (US)
- Priority review voucher (aGVHD); potentially worth tens or US$100+ million.
Mesoblast cash forecast
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |